Isomorphic Labs announced on November 17, 2026 that it has raised $5 billion in Series C funding. In its announcement, the AI drug-design company said the round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and several other new investors, with continued significant investment from Alphabet. All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The company said it is focused on designing and developing new medicines with AI and is scaling its proprietary drug design engine, IsoDDE, and a therapeutic candidate pipeline designed with AI. The page reviewed for this story did not give a valuation, a detailed use-of-funds breakdown or a clinical timeline.

Independent coverage supplies more detail. TechCrunch, in a report by Ram Iyer, described Isomorphic as the AI drug-discovery platform spun out of Google's DeepMind in 2021 and said the company reports positive preclinical results in oncology and immunology. It reported that the new round follows a $2.1 billion Series B in May, that Isomorphic has struck deals with pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson, and that the money will be used to keep developing the drug-design engine and to move into more types of medicine. TechCrunch also noted that this is the first fundraise since founder and CEO Demis Hassabis left his position as head of DeepMind to focus on drug discovery, moving into a chairman role there.

On valuation, TechCrunch wrote that Isomorphic did not disclose one and that Bloomberg reported earlier this month that the lab was seeking funding at a $50 billion valuation. That figure is Bloomberg's reporting as relayed by TechCrunch and is not confirmed by the company.

BioSpace described the round as the largest single biotech venture round on record, more than doubling Isomorphic's own Series B and exceeding the $3 billion debut raised by Altos Labs in 2022, and said Isomorphic has yet to publicly disclose any clinical assets. The Next Web, relaying Bloomberg interviews, reported that Hassabis said the funding will speed the move toward clinical trials, that Isomorphic has more than 20 programs underway, that it aims to expand beyond small molecules into most modalities including large-molecule biologics, and that the round was oversubscribed. The Next Web also noted that Hassabis said in January the company expected first clinical trials by the end of 2026 and would not give an updated target now, and that no regulator has yet approved an AI-designed drug.

The preclinical results, the number of programs and the platform's performance are company statements and have not been independently validated. Because the round has no disclosed valuation, readers should treat the $50 billion figure as unconfirmed.

References